Physicians' Academy for Cardiovascular Education

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Oct. 28, 2020 - Prof. John E Deanfield, MD - Online CME

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD

Why worry about high Lp(a) and how to asses Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD

Strong evidence for colchicine in patients with chronic coronary disease

5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

Cardiovascular outcomes & atherosclerosis: How do GLP-1RA provide benefit?

10' education - Sep. 24, 2020 - Jorge Plutzky, MD - Online CME

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach

High consumption of sugary drinks and ASBs associated with incident CVD

Literature - Oct. 29, 2020 - Chazelas E, et al. - J Am Coll Cardiol 2020
In a prospective study using data of a large French cohort, high consumption of sugary drinks and artificially-sweetened beverages increased risk of CVD.

In a prospective study using data of a large French cohort, high consumption of sugary drinks and artificially-sweetened beverages (ASBs) increased risk of CVD.

PCSK9 siRNA recommended by CHMP for EU approval

News - Oct. 28, 2020

Following the results from the ORION program, the CHMP of EMA has issued a positive opinion on inclisiran to reduce LDL-c in patients with hypercholesterolemia or mixed dyslipidemia.

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Oct. 28, 2020 - Prof. John E Deanfield, MD - Online CME
Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.

Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD
The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines.

The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.

AHA scientific statement on cardiorenal benefit with newer diabetes agents

News - Oct. 27, 2020

The AHA has published a scientific statement on evidence for the cardiorenal protective effects of SGLT2i and GLP-1RAs on outcomes in patients with CKD and T2DM.

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD
RNA therapeutics can reduce production of apo(a) in hepatocyten and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.

RNA therapeutics can reduce production of apo(a) in hepatocyten and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.

Total burden of serious CV events reduced by IL-1β inhibition

Literature - Oct. 26, 2020 - Everett BM et al. - J Am Coll Cardiol 2020

An analysis of the CANTOS trial showed that IL-1β inhibition with canakinumab reduced total number of serious CV events compared to placebo in patients with prior MI and subclinical inflammation.

Consistent effects with SGLT2 inhibitors in HFrEF in meta-analysis

Literature - Oct. 26, 2020 - Zannad F, et al. - The Lancet 2020

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials found no heterogeneity between effects of dapagliflozin and empagliflozin in HFrEF patients and a reduction in non-fatal and fatal CV outcomes and renal events with these SGLT2i.

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD
Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.

Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.

No difference in weight loss or metabolic markers with time-restricted eating

Literature - Oct. 21, 2020 - Lowe DA, et al. - JAMA Intern Med 2020

A randomized trial showed no effect of time-restricted eating on weight loss or metabolic markers compared to a standard 3-meals-per-day-diet in individuals with overweight or obesity.

Phase III trial with cardiac myosin activator meets primary endpoint in HFrEF patients

News - Oct. 21, 2020

The cardiac-specific myosin activator omecamtiv mecarbil significantly reduced the risk of CV death and HF events in HFrEF patients, yet failed to reduce CV death as secondary endpoint.

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD
RAAS inhibitors can cause hyperkalemia in HF patients. Javed Butler explains how novel potassium binders may improve management of patients with chronic HF by continuation of RAASi.

RAAS inhibitors can cause hyperkalemia in HF patients leading to RAASi downtitration or discontinuation. Novel potassium binders may improve management of HF patients by continuation of RAASi.